| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CMDC.201200272 |
| P8608 | Fatcat ID | release_4a7l7k5nz5dcbgwfztbt6jzzu4 |
| P698 | PubMed publication ID | 22865828 |
| P5875 | ResearchGate publication ID | 230620806 |
| P50 | author | Valérie Capra | Q41118843 |
| Angelo Sala | Q41118865 | ||
| Loretta Lazzarato | Q42417791 | ||
| Roberta Fruttero | Q42417799 | ||
| Barbara Rolando | Q57224478 | ||
| Massimo Bertinaria | Q60042121 | ||
| G.Enrico Rovati | Q64711258 | ||
| Malvina Hoxha | Q86833539 | ||
| Clara Cena | Q117276953 | ||
| Mohammed Abrar Abdul Gaffar Shaikh | Q117276961 | ||
| Carola Buccellati | Q117276962 | ||
| P2093 | author name string | Alberto Gasco | |
| P2860 | cites work | Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties | Q39459414 |
| Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations | Q39929202 | ||
| Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. | Q40978901 | ||
| Nitrooxymethyl-substituted analogues of rofecoxib: synthesis and pharmacological characterization | Q43057500 | ||
| Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk | Q43179593 | ||
| Development and biological evaluation of a novel aurora A kinase inhibitor | Q44055272 | ||
| Mutational analysis of the highly conserved ERY motif of the thromboxane A2 receptor: alternative role in G protein-coupled receptor signaling. | Q44960382 | ||
| Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial | Q57278179 | ||
| NO-Donor COX-2 Inhibitors. New Nitrooxy-Substituted 1,5-Diarylimidazoles Endowed with COX-2 Inhibitory and Vasodilator Properties | Q59545648 | ||
| THE AGGREGATION OF BLOOD PLATELETS | Q76530970 | ||
| Ligand-binding studies: old beliefs and new strategies | Q77455953 | ||
| Severe acute liver injury associated with lumiracoxib | Q82810248 | ||
| Rofecoxib analogues possessing a nitric oxide donor sulfohydroxamic acid (SO2NHOH) cyclooxygenase-2 pharmacophore: synthesis, molecular modeling, and biological evaluation as anti-inflammatory agents | Q85077313 | ||
| Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 | ||
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis | Q24601392 | ||
| A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385 | Q27641853 | ||
| Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles | Q28168230 | ||
| Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2 | Q28194441 | ||
| Assessment and prevention of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs | Q28200644 | ||
| LIGAND: A versatile computerized approach for characterization of ligand-binding systems | Q29547346 | ||
| Cyclooxygenases: structural, cellular, and molecular biology | Q29616510 | ||
| Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. | Q33178529 | ||
| Selective inhibitors of cyclooxygenase-2 (COX-2). | Q33922865 | ||
| Bioisosterism: A Rational Approach in Drug Design | Q34114437 | ||
| International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress | Q34200165 | ||
| Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities | Q34245387 | ||
| Coxibs and cardiovascular disease | Q34356732 | ||
| Nutritionally essential fatty acids and biologically indispensable cyclooxygenases | Q34729733 | ||
| Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 | Q34803113 | ||
| Distinct functions of COX-1 and COX-2. | Q34997943 | ||
| First and second generations of COX-2 selective inhibitors | Q35848204 | ||
| Adverse cardiovascular effects of the coxibs | Q36084983 | ||
| Cyclooxygenase inhibition and cardiovascular risk | Q36215336 | ||
| Designed multiple ligands. An emerging drug discovery paradigm | Q36284452 | ||
| Antagonism of thromboxane receptors by diclofenac and lumiracoxib | Q36358638 | ||
| Structural and functional basis of cyclooxygenase inhibition | Q36752887 | ||
| COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs | Q37061134 | ||
| Current status of COX-2 inhibitors | Q37066819 | ||
| Rescue strategies against non-steroidal anti-inflammatory drug-induced gastroduodenal damage | Q37580036 | ||
| Nitric oxide: a guardian for vascular grafts? | Q37887771 | ||
| Superactive mutants of thromboxane prostanoid receptor: functional and computational analysis of an active form alternative to constitutively active mutants | Q38344953 | ||
| Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage | Q38612976 | ||
| Cyclopentane-1,3-dione: a novel isostere for the carboxylic acid functional group. Application to the design of potent thromboxane (A2) receptor antagonists | Q38647071 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1647-1660 | |
| P577 | publication date | 2012-08-02 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors | |
| P478 | volume | 7 |
| Q38135433 | Inhibitors of the arachidonic acid cascade: interfering with multiple pathways |
| Q87877860 | Molecular docking, molecular modeling, and molecular dynamics studies of azaisoflavone as dual COX-2 inhibitors and TP receptor antagonists |
| Q94915326 | Polysubstituted Pyrimidines as mPGES-1 Inhibitors: Discovery of Potent Inhibitors of PGE2 Production with a Strong Anti-inflammatory Effects in Carrageenan-Induced Rat Paw Edema |
| Q38504675 | Prostanoids and NSAIDs in cardiovascular biology and disease |
| Q38260626 | Recent developments in chimeric NSAIDs as safer anti-inflammatory agents. |
| Q40122116 | Synthesis, Spectral Analysis, In Vitro Microbiological Evaluation, and Molecular Docking Studies of Some Novel 1-(1-Aryl-1H-tetrazol-5-yl)-2-(piperidin-1-yl)ethanone Derivatives |
Search more.